Teneligliptin therapy in nondiabetic obesity: GLP-1 enhancement and metabolic benefits

Summaries 2 min 767

Font Size

Created On: 26/04/2024

This randomized, prospective, double-blind, placebo-controlled, parallel-group study determined the impact of administering 20 mg Teneligliptin (oral antidiabetic agent) twice daily in conjunction with a low carbohydrate diet and regular physical exercise in obese individuals without diabetes.

See All

Key take away

In non-diabetic obese individuals, using 20 mg twice daily Teneligliptin is well-tolerated and remarkably improves GLP-1 levels, and reduces insulin resistance, body weight, triglyceride, appetite, and metabolic syndrome.

Background

Method

At an outpatient department of an endocrinology hospital, the study was carried out over a period of forty-eight weeks. Overall, 150 nondiabetic obese volunteers were randomly allocated into:

Test group (n=75): Received 20 mg Teneligliptin twice daily thirty minutes prior to meals (along with a low carbohydrate diet and regular physical exercise)
Control group (n=75): Received placebo twice daily thirty minutes prior to meals (along with a low carbohydrate diet and regular physical exercise)

Result

At the end of forty-eight weeks, remarkable improvements were observed in body weight, glucagon-like peptide-1 (GLP-1) levels, simplified nutrition assessment questionnaire (SNAQ) scores, homeostasis model assessment of insulin resistance (HOMA-IR), and triglyceride levels. The mean differences and 95% confidence intervals for GLP-1 (pg/mL) were 76.42 (44.42-148.41) (P = 0.37); SNAQ score, -1.64 (-2.48 to -0.81) (P = 0.000); HOMA-IR, -0.9 (-0.59 to -0.38) (P = 0.000); triglycerides (mg/dL), -29.37 (-44.46 to -14.07) (P = 0.000); and reduction in body weight (kilograms), -3.09 (-6.11 to -0.07) (P = 0.043).

Conclusion

Treatment with Teneligliptin resulted in vital improvements in GLP-1 levels, decreased insulin resistance, body weight, metabolic syndrome markers, triglyceride levels, and appetite. It was generally well-tolerated, except for instances of upper respiratory tract infections.

Source:

Metabolic Syndrome and Related Disorders

Link:

https://www.liebertpub.com/doi/abs/10.1089/met.2023.0218

Article:

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals